Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
160 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015', provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10 Therapeutics Development 11 Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 11 Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis 12 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 13 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes 15 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 20 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes 23 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 24 AstraZeneca PLC 24 Athersys, Inc. 25 Bayer AG 26 Betagenon AB 27 Cardiolynx AG 28 CardioVascular BioTherapeutics, Inc. 29 Celgene Corporation 30 Diffusion Pharmaceuticals LLC 31 DNAVEC Corporation 32 KunWha Pharmaceutical Co., Ltd. 33 MedImmune, LLC 34 miRagen Therapeutics, Inc. 35 Multi Gene Vascular Systems Ltd 36 Nuo Therapeutics, Inc. 37 Proteon Therapeutics, Inc. 38 Recardio GmbH 39 RegenoCELL Therapeutics, Inc. 40 Resverlogix Corp. 41 Sagene Pharmaceuticals, Inc. 42 Stemedica Cell Technologies, Inc. 43 Theravasc, Inc. 44 ViroMed Co., Ltd. 45 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Combination Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 (cilostazol + organic nitrate) ER - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 AEM-28 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ALD-301 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Annexin A-5 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 CVBT-141C - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 DVC1-0101 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 ELS-140 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 MEDI-6012 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Mesenchymal Stem Cells - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 MGN-6114 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 MultiGeneAngio - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 MultiGeneGraft - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 MultiStem - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 O-304 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 PDA-002 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 REC-03 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 rivaroxaban - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 RVX-208 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 sarpogrelate SR - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 selegiline + Antiplatelet Drugs - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 sodium nitrite SR - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 SYN-20112312RU - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 ticagrelor - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 transcrocetinate sodium - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 TXA-127 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 VM-202 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 vonapanitase - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates 105 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 144 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 148 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 149 Featured News & Press Releases 149 Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 149 Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 149 Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 150 Jul 09, 2014: Development Of Russian Innovative Drug For Peripheral Arterial Disease Is Supported By The Council Of Maryland Biotech Companies (USA) 151 Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session 152 Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 154 Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease 154 Oct 15, 2012: Proteon Therapeutics Initiates Patient Enrollment In Phase I Clinical Study Of PRT-201 In Patients Suffering From Peripheral Artery Disease 156 Jul 17, 2012: AstraZeneca To Initiate New Study Of BRILINTA In Patients With Peripheral Artery Disease 156 Nov 15, 2010: Diffusion Achieves Positive Results In Phase I/II Clinical Trial Of Trans Sodium Crocetinate In Peripheral Artery Disease 157 Appendix 159 Methodology 159 Coverage 159 Secondary Research 159 Primary Research 159 Expert Panel Validation 159 Contact Us 159 Disclaimer 160
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2015 11 Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2015 15 Comparative Analysis by Late Stage Development, H1 2015 16 Comparative Analysis by Clinical Stage Development, H1 2015 17 Comparative Analysis by Early Stage Development, H1 2015 18 Comparative Analysis by Unknown Stage Development, H1 2015 19 Products under Development by Companies, H1 2015 20 Products under Development by Companies, H1 2015 (Contd..1) 21 Products under Development by Companies, H1 2015 (Contd..2) 22 Products under Investigation by Universities/Institutes, H1 2015 23 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca PLC, H1 2015 24 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H1 2015 25 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H1 2015 26 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H1 2015 27 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cardiolynx AG, H1 2015 28 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 29 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H1 2015 30 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 31 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by DNAVEC Corporation, H1 2015 32 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by KunWha Pharmaceutical Co., Ltd., H1 2015 33 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by MedImmune, LLC, H1 2015 34 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H1 2015 35 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 36 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics, Inc., H1 2015 37 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H1 2015 38 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2015 39 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by RegenoCELL Therapeutics, Inc., H1 2015 40 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp., H1 2015 41 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 42 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 43 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H1 2015 44 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co., Ltd., H1 2015 45 Assessment by Monotherapy Products, H1 2015 46 Assessment by Combination Products, H1 2015 47 Number of Products by Stage and Target, H1 2015 49 Number of Products by Stage and Mechanism of Action, H1 2015 51 Number of Products by Stage and Route of Administration, H1 2015 53 Number of Products by Stage and Molecule Type, H1 2015 55 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics - Recent Pipeline Updates, H1 2015 105 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2015 144 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H1 2015 145 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..2), H1 2015 146 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..3), H1 2015 147 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2015 148
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
